Mild cognitive impairment and preclinical Alzheimer's disease

Geriatrics

Volumn 60, Issue 6 SUPPL., 2005, Pages 9-14

  Morris, John C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[25-35]; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIPARKINSON AGENT;

ALZHEIMER DISEASE; BRAIN INJURY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; HUMAN; PSYCHOMETRY; SYMPTOM; AGED; AGING; CLASSIFICATION; DAILY LIFE ACTIVITY; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; HUMANS; MEMANTINE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 20544441063     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.
2. Petersen RC. Conceptual overview. In: Petersen RC, ed. Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York, NY: Oxford University Press; 2003:1-14.
3. Petersen RC, Morris JC. Clinical features. In: Petersen RC, ed. Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York, NY: Oxford University Press; 2003:15-39.
4. Grundman M, Petersen RC, Ferris SH, et al; Alzheimer's Disease Cooperative Study. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.
5. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
6. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
7. Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 1996;17:365-371.
8. Taylor KI, Monsch AU. The neuropsychology of Alzheimer's disease. In: Richter RW, Richter BZ, eds. Current Clinical Neurology Series, Alzheimer's Disease: A Physician's Guide to Practical Management. Totowa, NJ: Humana Press Inc; 2003:109-120.
9. Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002; 59:1034-1041.
10. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
11. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol. 2004;11:734-741.
12. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105-2115.
13. Rosenberg RN. Advances in the molecular and genetic basis of Alzheimer's disease. In: Weiner MF, Lipton AM, eds. The Dementias: Diagnosis, Treatment, and Research. 3rd ed. Washington, DC: American Psychiatric Press, Inc; 2003.
14. Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002;4:119-126.
15. Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res. 2003;28:1705-1713.
16. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002;1:3
17. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448-452.
18. Frank RA, Galasko D, Hampel H, et al; National Institute on Aging Biological Markers Working Group. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging. 2003;24:521-536.
19. Morris JC. Dementia update 2003. Alzheimer Dis Assoc Disord. 2003;17:245-258.
20. Han X, Fagan AM, Cheng H, Morris JC, Xiong C, Holtzman DM. Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol. 2003;54:115-119.
21. Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med. 2004;10(Suppl):S34-S41.
22. Zamrini E, De Santi S, Tolar M. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiol Aging. 2004;25:685-691.
23. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.